What You Should Know: - Boston-based digital therapeutics leader Biofourmis
just closed a $100 million Series C funding round led by SoftBank,
bringing its total funding to $145M. - Biofourmis will be using the funding to develop, validate and commercialize several released and unreleased digital therapeutics solutions across cardiology, oncology, respiratory, and pain, with a focus on the United States and key Asian markets, including Asia Pacific, China, and
Read More
Biofourmis
Biofourmis Acquires Digital Therapeutics Oncology Startup Gaido Health
What You Should Know: - Boston-based digital therapeutics startup Biofourmis acquires LA-based Gaido Health from Takeda Pharmaceuticals, in a strategic deal that expands Biofourmis’ portfolio in the oncology space. - Gaido Health—a digital therapeutics company focused on the oncology market—was part of Takeda Digital Ventures, Takeda’s corporate technology investment and incubation arm. - With Gaido Health’s and Biofourmis’ dual focus on remote monitoring with wearables
Read More
What Health IT Thought Leaders Say HIMSS20 Would Have Focused On—If It Had Happened
What You Need to Know: Health IT thought leaders share what HIMSS20 would have focused On—if It had happened. - Hot topics include health IT to address COVID-19; artificial intelligence; EHR interoperability and usability; and more. –Kuldeep Singh Rajput, CEO of Biofourmis, Boston, Mass., which provides digital therapeutics that power personalized predictive care “Remote monitoring platforms and clinical-grade wearables combined with artificial intelligence [AI]-based
Read More
Hong Kong’s Dept. of Health Taps Biofourmis’ Remote Monitoring Platform to Fight Coronavirus
What You Need to Know: - Boston-based Biofourmis’ AI-powered digital therapeutics technology has inked a deal with The University of Hong Kong and Hong Kong’s Department of Health to leverage its wearable, AI-powered remote monitoring platform to provide new insights to fight COVID-19 in a national disease monitoring program. - Biofourmis’ technology will remotely monitor coronavirus infected and suspected patients and apply personally predictive analytics to help patients and increase
Read More
Analysis: November 2019 Health IT M&A Activity, Public Company Performance
– Healthcare Growth Partners' (HGP) summary of Health IT/digital health mergers & acquisition (M&A) activity, and public company performance during the month of November 2019We did a doubletake when we noticed all of the HGP healthcare indices climbed approximately 10% during the month of November. Year-to-date, the S&P 500 is up over 25% and the HGP healthcare indices are all hovering in that range. In the two month period since September, when talk of universal healthcare reached
Read More
Biofourmis Analytics Engine Receives FDA Clearance for Ambulatory Physiologic Monitoring
- Biofourmis received 510(k) clearance from the FDA for its Analytics Engine as a medical device for ambulatory physiological monitoring.- Milestone approval establishes an AI-powered solution as the foundation for future disease-specific predictive management tools from Biofourmis.- This FDA approval is the second market authorization for Biofourmis, having earned the agency's approval in May 2019 for its Biovitals RhythmAnalytics platform.Boston-based Biofourmis has received 510(K) clearance
Read More
CB Insights Unveils ‘Digital Health 150’ List of Startups Transforming Healthcare
- CB Insights unveils first-ever annual ‘Digital Health 150’ list of digital health startups working to transform the healthcare industry. - The Digital Health 150 companies span a wide spectrum of categories that involve all three key stakeholder groups for the healthcare industry — providers, payers, and patients. - A total of 17 companies on the list are unicorns (private companies valued at $1B+). Of these, 12 companies are US-based, 3 are based in China, 1 is based in France, and 1
Read More
Yale, Mayo Clinic, Biofourmis Launches Research to Detect Heart Failure Using Wearable Biosensor Data
Biofourmis has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). Biofourmis' mobile platform BiovitalsHFTM will be leveraged in a study of patients with heart failure to monitor functional capacity and quality of life to see if greater emphasis should be placed on these measures in the drug approval process.Impact of Heart FailureHeart failure afflicts approximately 6.5 million patients in the United States and
Read More
Biofourmis Lands $35M for AI-Powered Digital Therapeutics Platform
Biofourmis, a Boston, MA-based digital therapeutics platform, today announced that it has raised $35 million in Series B funding led by Sequoia Capital/Sequoia India and co-led by Mass Mutual. The latest funding round will enable the company to advance its proprietary artificialintelligence (AI)-powered digital therapeutics platform and pipeline that treats and manages a range of complex chronic conditions.Digital Therapeutics is Redefining The Healthcare Value ChainFounded in 2015, Biofourmis
Read More
